Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs
Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key patents covering chimeric antigen receptor (CAR) designs optimized for myeloid cells, including monocytes and macrophages.
Liberate Bio Demonstrates First In Vivo CAR-M–Mediated B-Cell Depletion in Non-Human Primates
Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, today announced new preclinical data presented at the American Society of Gene and Cell Therapies’ Advancing Cell and Gene Therapies for Cancer conference in Philadelphia.
Liberate Bio Announces Presentation to Update on RAPTOR LNP Platform and CAR-M Therapeutic Programs
Liberate Bio, Inc., a biotechnology company developing medicines which efficiently and selectively deliver payloads to immune cells while bypassing the live, announced an oral presentation by Melissa Deck - Director of Platform, demonstrating the success of Liberate’s RAPTOR™ screening platform and NHP data for the company’s first lead candidates at the Oligonucleotide and Peptide Therapeutics 2025 (TIDES) being held May 19th-22nd, 2025 in San Diego, California.
Liberate Bio Announces Presentation to Update on Advancements on their RAPTOR LNP Platform
Liberate Bio, Inc., a company delivering genetic medicines that transcend liver-based limitations, announced an oral presentation demonstrating the success of their RAPTOR™ screening platform and its first generation of extrahepatic lipid nanoparticles at the Oligonucleotide and Peptide Therapeutics 2024 (TIDES) being held May 14-17, 2024, in Boston, Massachusetts.
